Trials / Completed
CompletedNCT03523819
A Study of CS1002 in Subjects with Advanced Solid Tumors
A Phase Ia/Ib, Open-Label, Dose-Escalation, and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 As Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- CStone Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS1002 | Dose levels will be escalated following a modified 3+3 dose escalation scheme |
| DRUG | CS1003 | Fixed dose at 200mg in combination with CS1002 on a specified dose level |
Timeline
- Start date
- 2018-04-26
- Primary completion
- 2022-01-18
- Completion
- 2022-01-18
- First posted
- 2018-05-14
- Last updated
- 2024-09-19
Locations
10 sites across 2 countries: Australia, Hong Kong
Source: ClinicalTrials.gov record NCT03523819. Inclusion in this directory is not an endorsement.